6500 KB40 KB200520252025Anderluh, MarkoGobec, StanislavHrast, MartinaMinovski, NikolaZorman, Mašaštevilka:1letnik:76str. 10-21ISSN:0014-8229COBISSID_HOST:230959875URN:URN:NBN:SI:doc-6LIX8E8UslSlovensko farmacevtsko društvoFarmacevtski vestnikaminokumariniBakterijska rezistencakinoloninovi zaviralci bakterijskih topoizomerazprotibakterijska terapijazaviralci topoizomeraze tipa IIBoj proti bakterijski odpornosti| The fight against bacterial resistance| ali so bakterijske topoizomeraze tipa II še zanimive tarče?| are bacterial type II topoisomerases still interesting targets?|Type II topoisomerases are important targets for antibacterial therapy. The first inhibitors of type II topoisomerases, quinolones and aminocoumarins, emerged more than half a century ago, but their use is now in slow decline due to toxic side effects, low effectiveness and emergence of bacterial resistance. Innovations in this field – improvement of already existing classes of antibacterials and discovery of novel classes of compounds, are essential for overcoming resistance and maintaining topoisomerases as viable targets. In this paper, we present various classes of bacterial topoisomerase inhibitors, their advantages and shortcomings, as well as future perspectivesTopoizomeraze tipa II so pomembne tarče za proti - bakterijsko terapijo. Prvi zaviralci topoizomeraz tipa II, kinoloni in aminokumarini, so se na trgu pojavili že pred desetletji, vendar njihova uporabnost postopoma upada zaradi nizke učinkovitosti, neželenih učinkov in pojava bakterijske rezistence. Za premagovanje odpornosti in ohranjanje topoizomeraz kot zanimivih tarč, so ključne inovacije na tem področju – izboljšanje dosedanjih razredov učinkovin in odkrivanje novih tipov zaviralcev. V članku so predstavljeni različni razredi zaviralcev bakterijskih topoizomeraz, njihove prednosti in slabosti ter obeti za prihodnostTEXTznanstveno časopisjejournalsSlovenian National E-content AggregatorNational and University Library of SloveniaSlovensko farmacevtsko društvo